vidarabine has been researched along with Epidermolysis Bullosa Dystrophica in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Mathews, W; Muldoon, D; Tolar, J; Vanden Oever, M | 1 |
| Baxter-Lowe, L; Bruckner, A; Cairo, MS; Chen, M; Christiano, AM; Fabricatore, S; Geyer, MB; Giller, R; Harel, S; Kandel, J; Kiuru, M; LeBoeuf, N; McGrath, J; Morel, KD; Radhakrishnan, K; Uitto, J; Umegaki, N; Woodley, D | 1 |
3 other study(ies) available for vidarabine and Epidermolysis Bullosa Dystrophica
| Article | Year |
|---|---|
Fludarabine modulates expression of type VII collagen during haematopoietic stem cell transplantation for recessive dystrophic epidermolysis bullosa.
Topics: Collagen Type VII; Epidermolysis Bullosa Dystrophica; Hematopoietic Stem Cell Transplantation; Humans; Phosphatidylinositol 3-Kinases; Vidarabine | 2021 |
Does fludarabine have a beneficial effect in recessive dystrophic epidermolysis bullosa?
Topics: Collagen Type VII; Epidermolysis Bullosa Dystrophica; Humans; Skin; Vidarabine | 2021 |
Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Epithelial Cells; Fibroblasts; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Mutation; Myeloablative Agonists; RNA, Messenger; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |